120例早发型子痫前期孕妇解痉抗凝治疗的临床分析

目的:探讨早发型子痫前期患者应用硫酸镁合并低分子肝素及丹参期待治疗的临床效果和安全性。方法:将2008年10月至2011年5月来我院就诊的早发型子痫前期孕妇随机分为4组(共120例)。A组:硫酸镁常规治疗;B组:硫酸镁+丹参(20ml/d)治疗;C组:硫酸镁+低分子肝素(4100U/d)治疗;D组:硫酸镁+丹参(20ml/d)+低分子肝素(4100U/d)治疗。通过临床症状、体征及辅助检查的变化判断各组的治疗效果及其对母婴的影响。结果:4组患者在治疗前临床各项指标差异无统计学意义(P>0.05);4组治疗后平均动脉压均较治疗前下降(P<0.05),24小时尿蛋白治疗前后差异无统计学意义;治疗后B、C、D3组的新生儿窒息率较A组显著降低(P<0.05),而在B、C、D各组间比较差异无统计学意义(P>0.05)。结论:硫酸镁联合低分子肝素或丹参治疗可改善早发型子痫前期患者新生儿的预后,安全有效。

Clinical Analysis of Spasmolysis and Anticoagulant Therapy in 120 Cases of Early-Onset Preeclampsia

Objective:To investigate the effectiveness and security of magnesium sulfate combined with low molecular heparin and/or tanshinone therapy for early onset preeclampsia.Methods:From October 2008 to May 2011 120 early onset preeclampsia patients in our hospital were randomly divided into four groups.Group A:magnesium sulfate conventional treatment;Group B:magnesium sulfate+tanshinone(20 ml daily);Group C:magnesium sulfate+low molecular heparin(4100 U daily);Group D:Magnesium sulfate+tanshinone(20 ml daily)+low molecular heparin(4100 U daily).The clinical symptoms and signs as well as laboratory data were collected and analyzed to evaluate the therapeutic effectiveness and influence on mother and fetus in these four therapy protocols.Results:There was no statistical difference in clinical index among these four groups before treatment(P>0.05).After treatment,the rate of neonatal asphyxia in group B,C,D was significantly lower than group A(P<0.05),but no difference was found among B,C and D group.Conclusions:Magnesium sulfate combined with low molecular heparin or tanshinone can significantly improve the neonatal outcomes in early onset preeclampsia,which is effective and safe.